down arrow

Revance Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: US7613301099
USD
3.65
0.00 (0.00%)

Feb 07

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Ligand Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc.
SAGE Therapeutics, Inc.
ImmunityBio, Inc.
MannKind Corp.
Revance Therapeutics, Inc.
Day One Biopharmaceuticals, Inc.
Morphic Holding, Inc.
Viking Therapeutics, Inc.
89bio, Inc.
EQRx, Inc.
Why is Revance Therapeutics, Inc. ?
1
Flat results in Sep 24
  • DEBTORS TURNOVER RATIO(HY) Lowest at 6.71%
  • CASH AND EQV(HY) Lowest at USD 417.06 MM
  • INVENTORY TURNOVER RATIO(HY) Lowest at 1.12%
2
Risky - Not traded in last 10 days
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 0%, its profits have risen by 28.1%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals: Major)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Revance Therapeutics, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Revance Therapeutics, Inc.
-32.16%
-0.22
143.05%
S&P 500
13.22%
0.61
20.23%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
201.03%
EBIT Growth (5y)
-1.22%
EBIT to Interest (avg)
-18.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.62
Sales to Capital Employed (avg)
0.54
Tax Ratio
0.84%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-2.34
EV to EBIT
-3.88
EV to EBITDA
-4.03
EV to Capital Employed
6.40
EV to Sales
2.61
PEG Ratio
NA
Dividend Yield
84.25%
ROCE (Latest)
-164.63%
ROE (Latest)
Negative BV
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Icon
Not enough Data to analyse Financial Trend
Icon
Not enough Data to analyse Financial Trend
Here's what is working for Revance Therapeutics, Inc.
Operating Cash Flow
Highest at USD -190.89 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Profit
Higher at USD -75.64 MM
than preceding 12 month period ended Sep 2024
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Operating Profit
Highest at USD -31.02 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit
Highest at USD -36.62 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Raw Material Cost
Fallen by -2.65% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Revance Therapeutics, Inc.
Interest
At USD 6.73 MM has Grown at 18.54%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Debtors Turnover Ratio
Lowest at 6.71% and Fallen
In each half year in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Interest
Highest at USD 6.73 MM
in the last five periods and Increased by 18.54% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Cash and Eqv
Lowest at USD 417.06 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Inventory Turnover Ratio
Lowest at 1.12%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."